Mal-(CH2)5-Val-Cit-PAB-Eribulin

位置：首页 > 产品库 > Mal-(CH2)5-Val-Cit-PAB-Eribulin

立即咨询

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

2130869-21-3

包装与价格：

Mal-(CH2)5-Val-Cit-PAB-Eribulin 是抗体偶联药物的一部分 (drug-linker conjugate for ADC)，具有抗癌活性，它由抗微管剂Eribulin 和linker Mal-(CH2)5-Val-Cit-PAB 组成。

Cas No.	2130869-21-3
分子式	C₆₉H₉₇N₇O₁₉
分子量	1328.54
储存条件	4°C, protect from light, stored under nitrogen
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request
产品描述	Mal-(CH2)5-Val-Cit-PAB-Eribulin is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-microtubule agent, Eribulin, linked via linker Mal-(CH2)5-Val-Cit-PAB[1]. Eribulin (E7389) is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules[2]. [1]. Earl F Albone, et al. Eribulin-based antibody-drug conjugates and methods of use. Patent US20170252458A1. [2]. Watanabe K, et, al. Low-dose eribulin reduces lung metastasis of osteosarcoma in vitro and in vivo. Oncotarget. 2019 Jan 4; 10(2): 161-174.